Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司
For research, development and manufacturing use only. Not for human or veterinary use.

Metabolic & Weight Loss · Source-reviewed dossier

AICAR

Source-Reviewed Research Dossier

AICAR is a laboratory compound used mainly to study AMPK, a cell's energy sensor. Cells convert it into a molecule that looks like AMP, which can switch on AMPK. But it also affects other processes, so researchers do not treat it as a clean, AMPK-only tool. A systematic review found important effects that occur without AMPK. A mouse study of diabetic nerve damage reported that treatment prevented or reversed nerve problems and changed how damaged mitochondria were cleared, alongside effects on insulin, glucose and lipids. These are cell and animal findings. Human outcomes are not established.

Research use only Lot documents on request
AICAR research product family with 1 catalog variants
AI-generated packaging mockup for catalog navigation. It is not a photograph of an actual supplied lot; container, label and presentation may vary.

Product family

Compound overview

Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.

Product identity

Product type
Small-molecule research compound
Catalog family
AICAR
Research category
Metabolic & Weight Loss
Catalog CAS RN
2627-69-2
Catalog molecular formula
C9H14N4O5
Catalog molecular weight
258.23 g/mol
Evidence status
Extensive cell and animal research; AMPK-dependent and independent effects
Intended use
Research, development and manufacturing use only

Literature reference parameters

Compound or material class
Adenosine analogue / AMP-mimetic research compoundCatalog-family identity
Evidence scope
Extensive cell and animal research; AMPK-dependent and independent effectsDo not generalize beyond the cited model
Source review
Primary or authoritative records linked belowChecked 2026-09-01

Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.

Mechanism of action

How AICAR is studied

A target-to-pathway view grounded in the linked research records.

Becomes an AMP-like signal

Cells take up AICAR and change it into a form that resembles AMP, the molecule that rises when a cell's energy falls. This mimic can occupy AMP-sensitive sites and trigger energy-sensing responses even when the cell is not truly low on fuel. It is studied as a laboratory tool, not a natural metabolite. Response strength depends on cell type, amount used and exposure time.

Energy sensing in nerve tissue

AMPK acts like a fuel monitor that coordinates a cell's response to changing energy supply. In a mouse study of diabetic nerve damage, AICAR increased activated AMPK in nerve tissue. But AICAR also affects pathways that do not need AMPK, so no single protective result can be credited to AMPK alone. This remains an animal-model finding.

Effects without AMPK

A systematic review warns that many actions credited to AMPK still happen when AMPK is removed or blocked. That means AICAR and its active form can affect nucleotide synthesis, oxygen-sensing pathways and other cell processes on their own. So a positive AICAR result cannot automatically be called an AMPK effect. Careful studies use controls to separate the two.

Nerve protection in diabetic mice

In diabetic mouse models, AICAR treatment prevented or reversed measured nerve damage, with changes related to clearing damaged mitochondria, the structures that help cells make energy. Because glucose, insulin and lipid effects also contributed, no single cause is established. These findings support nerve-metabolism research; they do not show treatment benefits in people.

What the experiment does not establish

AICAR supplied for laboratory work is a defined small molecule, not a finished medicine, and it has not been shown to be safe or effective for human use. Identity, purity and lot handling are separate questions addressed by specifications and analytical documents. Cell or animal findings should not be transferred to other compounds, salt forms, blends or routes without direct evidence. Reviews summarize past experiments, not new results.

Reported research findings

What published studies report about AICAR

Reported outcomes are paired with their experimental model and evidence boundary.

Systematic review

AICAR is not a selective one-pathway probe

A systematic review catalogued widely reported AMPK activation together with important AMPK-independent effects.

Experimental conclusions require controls that separate AMPK dependence from other AICAR/ZMP actions.

Read the primary study
Animal study

Mitophagy-related outcomes were reported in diabetic neuropathy models

A 2024 animal study reported prevention and reversal of diabetic-polyneuropathy measures alongside mitophagy-related changes.

Rodent disease-model findings do not establish clinical outcomes or catalog-lot performance.

Read the primary study
Translation boundary: findings are limited to the evidence level stated on each card. Experimental protocol quantities are research details, not usage instructions.

Catalog options

Variant specifications

Pack-level catalog data; lot-level controls remain document-specific.

Catalog no.AR50
Pack size50 mg × 10 vials
Current variant
Specification & documents for AR50

Product specification

Small-molecule research compound · 50 mg/vial nominal · 10-vial pack · chemical form, identity and assay controlled by lot specification.

Lot documentation

Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.

Quality system

Quality documentation

A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.

Lot-specific Certificate of AnalysisAvailability and scope must be confirmed for the selected catalog variant and lot
COA availability unconfirmed Ask about availability
Product Specification SheetAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request
Analytical Method SummaryAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request

Analytical interpretation

Interpret the documents, not just the headline number.

Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.

Open the Quality & Documentation Hub

HPLC area ≠ assayA dominant peak does not establish target mass fraction.

Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.

Counterions affect contentWater, salt form and solvents change the as-is composition.

Storage needs a data basisShipping practice is not the same as stability evidence.

Evidence map

Research context

Published studies and regulatory records, not customer testimonials or usage guidance.

Systematic review

AICAR is not a selective one-pathway probe

Experimental conclusions require controls that separate AMPK dependence from other AICAR/ZMP actions.

View primary record
Animal study

Mitophagy-related outcomes were reported in diabetic neuropathy models

Rodent disease-model findings do not establish clinical outcomes or catalog-lot performance.

View primary record
Evidence boundary: each card states its evidence type. Human trials and regulatory records describe the studied or regulated intervention; preclinical records remain model-specific. None verifies the identity, quality, safety or efficacy of this catalog lot or provides usage instructions.

Literature basis

Curated references

Third-party publications selected for direct relevance.

  1. 01 Systematic review
  2. 02 Animal study

Research FAQ

AICAR questions

Concise answers for researchers comparing identity, evidence and catalog variants.

What effects are studied for AICAR?

AICAR is mainly used to study AMPK signaling and cellular energy sensing, and it has been tested in models of metabolism and diabetes complications. A systematic review found it is not selective for AMPK because important effects occur without it. A mouse study reported prevention or reversal of diabetic neuropathy measures alongside changes in clearing damaged mitochondria, while also affecting insulin, glucose and lipid handling. These are laboratory and animal findings, not human benefit.

How should the AICAR research findings be understood?

AICAR supplied for laboratory work is a defined small molecule, not a finished medicine, and it has not been shown to be safe or effective for human use. Identity, purity and lot handling are separate questions addressed by specifications and analytical documents. Cell or animal findings should not be transferred to other compounds, salt forms, blends or routes without direct evidence. Reviews summarize past experiments, not new results.

What evidence is available for AICAR?

The evidence base is predominantly mechanistic and preclinical, with a systematic review documenting both AMPK-linked and independent actions.

Does the cited research validate this catalog material?

No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.

Which quality documents can be requested?

A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.

How should AICAR be stored?

Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.

Knowledge center

Related insights

Owned educational content connected to this family.

Editorial comic illustration: AICAR Identity Guide. Conceptual cover, not experimental imagery.

AICAR Identity Guide: Acadesine, ZMP and the AMPK Evidence Boundary

AICAR naming often collapses acadesine, its intracellular phosphorylated metabolite ZMP and an entire AMPK pathway into one label. Reproducible research needs those three concepts…

Updated October 1, 2026

Knowledge tools

Continue with structured evidence

Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.

Internal technical source review

Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.

Editorial status: NHD evidence editorial workflow · 2026-09-01 · Not independent medical review · Review policy

Technical procurement

Ready to request a quote?

Selected: AR50 · 50 mg × 10 vials